

Refine Search

Search Results -

Terms	Documents
L1 same homeopathic	10

Database:

US Pre-Grant Publication Full-Text Database
 US Patents Full-Text Database
 US OCR Full-Text Database
 EPO Abstracts Database
 JPO Abstracts Database
 Derwent World Patents Index
 IBM Technical Disclosure Bulletins

Search:

L2

Refine Search

Recall Text

Clear

Interrupt

Search History

DATE: Tuesday, July 27, 2004 [Printable Copy](#) [Create Case](#)

<u>Set</u> <u>Name</u> side by side	<u>Query</u>	<u>Hit</u> <u>Count</u>	<u>Set</u> <u>Name</u> result set
<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; PLUR=YES; OP=OR</i>			
<u>L2</u>	L1 same homeopathic	10	<u>L2</u>
<u>L1</u>	insulin-like adj growth adj factor or insulin adj like adj growth adj factor or IGF-1	10505	<u>L1</u>

END OF SEARCH HISTORY

WEST Search History

[Hide Items](#)[Restore](#)[Clear](#)[Cancel](#)

DATE: Tuesday, July 27, 2004

Hide?	<u>Set Name</u>	<u>Query</u>	<u>Hit Count</u>
		<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; PLUR=YES; OP=OR</i>	
<input type="checkbox"/>	L4	L3 same homeopathic	34
<input type="checkbox"/>	L3	growth adj factor\$	62308
<input type="checkbox"/>	L2	L1 same homeopathic	10
<input type="checkbox"/>	L1	insulin-like adj growth adj factor or insulin adj like adj growth adj factor or IGF-1	10505

END OF SEARCH HISTORY

Refine Search

Search Results -

Terms	Documents
(igf-1 or insulin-like adj growth adj factor-1) with (composition or dose)	190

Database:

US Pre-Grant Publication Full-Text Database
 US Patents Full-Text Database
 US OCR Full-Text Database
 EPO Abstracts Database
 JPO Abstracts Database
 Derwent World Patents Index
 IBM Technical Disclosure Bulletins

Search:

L3

Refine Search

Recall Text

Clear

Interrupt

Search History

DATE: Tuesday, August 10, 2004 [Printable Copy](#) [Create Case](#)

<u>Set</u> <u>Name</u> side by side	<u>Query</u>	<u>Hit</u> <u>Count</u>	<u>Set</u> <u>Name</u> result set
	<i>DB=USPT; PLUR=YES; OP=OR</i>		
<u>L3</u>	(igf-1 or insulin-like adj growth adj factor-1) with (composition or dose)	190	<u>L3</u>
<u>L2</u>	(igf-1 or insulin-like adj growth adj factor-1) same (composition or dose)	356	<u>L2</u>
<u>L1</u>	(igf-1 or insulin-like adj growth adj factor) same (composition or dose)	788	<u>L1</u>

END OF SEARCH HISTORY

L3 ANSWER 1 OF 10 USPATFULL on STN
 ACCESSION NUMBER: 2003:271454 USPATFULL
 TITLE: Treatment methods using homeopathic preparations of growth factors
 INVENTOR(S): Brewitt, Barbara A., Seattle, WA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003191061	A1	20031009
APPLICATION INFO.:	US 2002-304635	A1	20021126 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2000-499230, filed on 7 Feb 2000, GRANTED, Pat. No. US 6485480 Division of Ser. No. US 1997-855096, filed on 13 May 1997, GRANTED, Pat. No. US 6024734 Continuation-in-part of Ser. No. US 1996-710040, filed on 10 Sep 1996, GRANTED, Pat. No. US 5629286 Continuation of Ser. No. US 1995-488722, filed on 8 Jun 1995, ABANDONED Continuation-in-part of Ser. No. US 1994-221365, filed on 31 Mar 1994, ABANDONED Continuation-in-part of Ser. No. US 2001-1367, filed on 30 Oct 2001, PENDING Continuation-in-part of Ser. No. US 2001-870132, filed on 29 May 2001, ABANDONED Continuation of Ser. No. US 1999-251820, filed on 17 Feb 1999, GRANTED, Pat. No. US 6239105 Continuation-in-part of Ser. No. US 1997-855096, filed on 13 May 1997, GRANTED, Pat. No. US 6024734 Continuation-in-part of Ser. No. US 1996-710040, filed on 10 Sep 1996, GRANTED, Pat. No. US 5629286 Continuation of Ser. No. US 1995-488722, filed on 8 Jun 1995, ABANDONED Continuation-in-part of Ser. No. US 1994-221365, filed on 31 Mar 1994, ABANDONED		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	SPECKMAN LAW GROUP, 1501 WESTERN AVE, SUITE 100, SEATTLE, WA, 98101		
NUMBER OF CLAIMS:	14		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	35 Drawing Page(s)		
LINE COUNT:	2546		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.			

AB The present invention comprises homeopathic preparations of growth factors, cyclins, and methods for their use. Disorders which may be effectively treated with the compositions of the present invention include chronic viral disorders, such as HIV, AIDS, chronic fatigue syndrome and Epstein-Barr viral infections, cancer, diabetes, depression, and autism. Homeopathic preparations of growth factors and/or cyclins are preferably administered orally. In an alternative embodiment, patients are treated with radio frequency signals corresponding to homeopathic dilutions of growth factors.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 2 OF 10 PROMT COPYRIGHT 2004 Gale Group on STN

ACCESSION NUMBER: 2002:181936 PROMT
 TITLE: Joshua Tree, dba Nutritionary, Announces the Release of Three Weight Loss Products.
 SOURCE: Business Wire, (25 Mar 2002) pp. 2341.
 PUBLISHER: Business Wire
 DOCUMENT TYPE: Newsletter
 LANGUAGE: English
 WORD COUNT: 775
 FULL TEXT IS AVAILABLE IN THE ALL FORMAT

AB Business Editors/Health & Medical Writers
THIS IS THE FULL TEXT: COPYRIGHT 2002 Business Wire

L3 ANSWER 3 OF 10 USPATFULL on STN DUPLICATE 1
ACCESSION NUMBER: 2002:92896 USPATFULL
TITLE: Homeopathic preparations
INVENTOR(S): Brewitt, Barbara A., Seattle, WA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002049422	A1	20020425
APPLICATION INFO.:	US 2001-1367	A1	20011030 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2001-870132, filed on 29 May 2001, PENDING Continuation of Ser. No. US 1999-251820, filed on 17 Feb 1999, PATENTED Continuation-in-part of Ser. No. US 1997-855096, filed on 13 May 1997, PATENTED Continuation-in-part of Ser. No. US 1996-710040, filed on 10 Sep 1996, PATENTED Continuation of Ser. No. US 1995-488722, filed on 8 Jun 1995, ABANDONED Continuation-in-part of Ser. No. US 1994-221365, filed on 31 Mar 1994, ABANDONED		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-255958P	20001215 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Ann W. Speckman, SPECKMAN LAW GROUP, Suite 100, 1501 Western Avenue, Seattle, WA, 98101	
NUMBER OF CLAIMS:	15	
EXEMPLARY CLAIM:	1	
LINE COUNT:	951	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

AB The present invention comprises homeopathic preparations of a purified protein described herein, as well as methods and systems for delivery of such preparations and treatment of disorders and conditions by administering such preparations.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 4 OF 10 USPATFULL on STN DUPLICATE 2
ACCESSION NUMBER: 2002:310444 USPATFULL
TITLE: Treatment methods using homeopathic preparations of growth factors
INVENTOR(S): Brewitt, Barbara A., 5557 36thAve. NE., Seattle, WA, United States 98105

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6485480	B1	20021126
APPLICATION INFO.:	US 2000-499230		20000207 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1997-855096, filed on 13 May 1997, now patented, Pat. No. US 6024734 Continuation-in-part of Ser. No. US 1996-710040, filed on 10 Sep 1996, now patented, Pat. No. US 5629286, issued on 13 May 1997 Continuation of Ser. No. US 1995-488722, filed on 8 Jun 1995, now abandoned Continuation-in-part of Ser. No. US 1994-221365, filed on 31 Mar 1994, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Casler, Brian L.		
ASSISTANT EXAMINER:	Thissell, Jeremy		

LEGAL REPRESENTATIVE: Speckman, Ann W., Klaniecki, James E., Benado, Lisa N.
NUMBER OF CLAIMS: 16
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 38 Drawing Figure(s); 34 Drawing Page(s)
LINE COUNT: 1892

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention comprises homeopathic dilutions of growth factors and methods for their use. Disorders which may be effectively treated with the compositions of the present invention include chronic viral disorders, such as HIV, AIDS, chronic fatigue syndrome and Epstein-Barr viral infections, cancer, diabetes and depression. Homeopathic dilutions of growth factors are preferably administered orally. In an alternative embodiment, patients are treated with radio frequency signals corresponding to homeopathic dilutions of growth factors.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 5 OF 10 USPATFULL on STN
ACCESSION NUMBER: 2002:140892 USPATFULL
TITLE: Homeopathic preparations
INVENTOR(S): Brewitt, Barbara A., Seattle, WA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002071873	A1	20020613
APPLICATION INFO.:	US 2001-870132	A1	20010529 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1999-251820, filed on 17 Feb 1999, PATENTED Continuation-in-part of Ser. No. US 1997-855096, filed on 13 May 1997, PATENTED Continuation-in-part of Ser. No. US 1996-710040, filed on 10 Sep 1996, PATENTED Continuation of Ser. No. US 1995-488722, filed on 8 Jun 1995, ABANDONED Continuation-in-part of Ser. No. US 1994-221365, filed on 31 Mar 1994, ABANDONED		

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: SPECHMAN LAW GROUP, 1501 WESTERN AVE, SUITE 100, SEATTLE, WA, 98101

NUMBER OF CLAIMS: 1
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 16 Drawing Page(s)
LINE COUNT: 1014

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention comprises homeopathic preparations of a purified growth factor, as well as methods and systems for delivery of such preparations and treatment of disorders and conditions by administering such preparations.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 6 OF 10 PROMT COPYRIGHT 2004 Gale Group on STN

ACCESSION NUMBER: 2001:316693 PROMT
TITLE: Biomed Comm Homeopathic Preparation Chewable Tablets - Ease
MANUFACTURER: Biomed Comm, Inc. CATEGORY: 350 - Pain Relief.
SOURCE: Product Alert, (23 Apr 2001) Vol. 31, No. 8.
ISSN: 0740-3801.

PUBLISHER: Marketing Intelligence Service Ltd.

DOCUMENT TYPE: Newsletter

LANGUAGE: English

WORD COUNT: 80

FULL TEXT IS AVAILABLE IN THE ALL FORMAT

AB The Biomed Comm line of **Homeopathic** Preparation products includes Ease. The Chewable Tablets are sold in a 15-count plastic bottle that states, "Reliable fast relief." Its formula, said to use a 6C pure recombinant **IGF-1**, "may relieve many physical and psychological discomforts due to cyclical hormonal imbalance, including breast tenderness, joint soreness, headaches, cramps and bloating." The product is manufactured by Biomed Comm, Inc., located in Seattle, WA. For sample retrieval information, please call: Marketing Intelligence Service, Ltd., (716) 374-6326.

THIS IS THE FULL TEXT: COPYRIGHT 2001 Marketing Intelligence Service Ltd.

Subscription: \$600.00 per year. Published semimonthly. 6473 D Route 64, Naples, NY 14512-9726.

L3 ANSWER 7 OF 10 USPATFULL on STN

ACCESSION NUMBER: 2001:79130 USPATFULL
TITLE: Homeopathic preparations of purified growth hormone
INVENTOR(S): Brewitt, Barbara A., 5557 36th Ave. NE., Seattle, WA, United States 98107
PATENT ASSIGNEE(S): Brewitt, Barbara A., Seattle, WA, United States (U.S. individual)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6239105	B1	20010529
APPLICATION INFO.:	US 1999-251820		19990217 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1997-855096, filed on 13 May 1997, now patented, Pat. No. US 6024734 Continuation-in-part of Ser. No. US 1996-710040, filed on 10 Sep 1996, now patented, Pat. No. US 5629286, issued on 13 May 1997 Continuation of Ser. No. US 1995-488722, filed on 8 Jun 1995, now abandoned Continuation-in-part of Ser. No. US 1994-221365, filed on 31 Mar 1994, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Moezie, F. T.		
LEGAL REPRESENTATIVE:	Speckman, Ann W.		
NUMBER OF CLAIMS:	19		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	31 Drawing Figure(s); 16 Drawing Page(s)		
LINE COUNT:	1063		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention comprises homeopathic preparations of purified growth hormone, as well as methods and systems for delivery of such preparations and treatment of disorders and conditions by administering such preparations.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 8 OF 10 USPATFULL on STN

DUPLICATE 3

ACCESSION NUMBER: 2000:17822 USPATFULL
TITLE: Treatment methods using homeopathic preparations of growth factors
INVENTOR(S): Brewitt, Barbara A., 5557 36.sup.th Ave. NE., Seattle, WA, United States 98105

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6024734		20000215
APPLICATION INFO.:	US 1997-855096		19970513 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1996-710040, filed on 10 Sep 1996, now patented, Pat. No. US 5629286,		

issued on 13 May 1997 which is a continuation of Ser.
No. US 1995-488722, filed on 8 Jun 1995, now abandoned
which is a continuation-in-part of Ser. No. US
1994-221365, filed on 31 Mar 1994, now abandoned

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: McDermott, Corrine
ASSISTANT EXAMINER: Gring, Kent
LEGAL REPRESENTATIVE: Speckman, Ann W., Sleath, Janet
NUMBER OF CLAIMS: 21
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 30 Drawing Figure(s); 34 Drawing Page(s)
LINE COUNT: 2005

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention comprises homeopathic dilutions of growth factors and methods for their use. Disorders which may be effectively treated with the compositions of the present invention include chronic viral disorders, such as HIV, AIDS, chronic fatigue syndrome and Epstein-Barr viral infections, cancer, diabetes and depression. Homeopathic dilutions of growth factors are preferably administered orally. In an alternative embodiment, patients are treated with radio frequency signals corresponding to homeopathic dilutions of growth factors.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 9 OF 10 WPIDS COPYRIGHT 2004 THOMSON DERWENT on STN DUPLICATE 4

ACCESSION NUMBER: 2000-587749 [56] WPIDS
CROSS REFERENCE: 1995-358410 [46]; 1997-280299 [25]; 2000-181780 [16];
2002-425533 [45]; 2003-310423 [30]; 2003-831663 [77]

DOC. NO. CPI: C2000-175390

TITLE: Novel homeopathic preparation comprising a homeopathic potency of purified growth hormone for modulating effects of aging, reducing blood pressure, increasing serum insulin-like growth factor levels, lean body mass.

DERWENT CLASS: B04 D16
INVENTOR(S): BREWITT, B A
PATENT ASSIGNEE(S): (BIOM-N) BIOMED COMM INC; (BREW-I) BREWITT B A
COUNTRY COUNT: 4
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
AU 2000018455	A	20000824	(200056)*		21
JP 2000302691	A	20001031	(200059)		16
ZA 2000000771	A	20001227	(200103)		21
US 6239105	B1	20010529	(200132)		
US 2002071873	A1	20020613	(200243)		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
AU 2000018455	A	AU 2000-18455	20000217
JP 2000302691	A	JP 2000-38624	20000216
ZA 2000000771	A	ZA 2000-771	20000217
US 6239105	B1	CIP of US 1994-221365	19940331
		Cont of US 1995-488722	19950608
		CIP of US 1996-710040	19960910
		CIP of US 1997-855096	19970513
		US 1999-251820	19990217
US 2002071873	A1	CIP of US 1994-221365	19940331
		Cont of US 1995-488722	19950608
		CIP of US 1996-710040	19960910

CIP of	US 1997-855096	19970513
Cont of	US 1999-251820	19990217
	US 2001-870132	20010529

FILING DETAILS:

PATENT NO	KIND	PATENT NO
US 6239105	B1 CIP of CIP of	US 5629286 US 6024734

PRIORITY APPLN. INFO: US 1999-251820 19990217; US
1994-221365 19940331; US
1995-488722 19950608; US
1996-710040 19960910; US
1997-855096 19970513; US
2001-870132 20010529

AN 2000-587749 [56] WPIDS
CR 1995-358410 [46]; 1997-280299 [25]; 2000-181780 [16]; 2002-425533 [45];
2003-310423 [30]; 2003-831663 [77]

AB AU 200018455 A UPAB: 20031128
NOVELTY - A homeopathic preparation (I) comprising a homeopathic potency
of purified growth hormone, is new.
ACTIVITY - Nootropic; neuroprotective; antiparkinsonian; osteopathic.
No supporting data given.
MECHANISM OF ACTION - Growth promoter; regulator of cell growth and
differentiation.

Studies were conducted on healthy adult subjects to ascertain the
effect of various potencies of recombinant human growth hormone (rhGH).
Three studies were conducted in the format of double-blind, placebo
controlled studies (DBPCS). In the first study, which was a thirty day
DBPCS, subjects were randomly divided into two groups; one group received
a combination 6C+100C+200C **homeopathic** hGH formulation and the
other group received placebo. In the second study, individuals were given
a placebo in a bottle and instructed to take one chewable tablet three
times per day for seven days and after seven days of treatment, subjects
were given a bottle which contained a single potency of either 6X or 6C or
placebo. The third study was a placebo controlled study with crossover
after 21 days to the opposite test substance. A group initially received
placebo and after 21 days received treatment with a **homeopathic**
preparation. Blood samples were taken from all the groups to determine
serum **IGF-1** levels. Reproducible rises in serum
IGF-1 were observed in all three studies.

USE - For modulating the effects of aging and for modulating lean
body mass (claimed). (I) has significant anabolic and anti-catabolic
effects on the body and is useful for increasing serum IGF-1 levels, lean
body mass, muscle mass, libido and sex hormones, energy levels, cartilage
strength, and size and function of the thymus, spleen, treating growth
deficiency disorders, improving cardiovascular function, endurance, skin
tone, lipoprotein balance, fatty acid levels, and cholesterol profile,
enhancing immune system function, promoting hair growth and color change,
reducing blood pressure, joint, back and knee pain, bleeding of the gums,
nasal and sinus congestion, and fat, in particular, hip size, upper arm
size and waist size. (I) is also useful for improving short term memory,
reducing the manifestations of anger, anxiety, depression, social
isolation, mood swings and sleeping disorders, improving vision, removing
wrinkles, accelerating wound healing, facilitating breast enlargement and
generally contributing to a feeling of well-being. (I) may also be useful
to treat headaches, AIDS wasting syndrome, Turner syndrome, osteoporosis,
Parkinson's, Alzheimer's disease and dementia.

ADVANTAGE - (I) is non-toxic, do not produce undesirable side effects
and can be formulated and provided to a large patient population at a
reasonable cost by means of delivery systems that are convenient and safe.

L3 ANSWER 10 OF 10 VETU COPYRIGHT 2004 THOMSON DERWENT on STN

ACCESSION NUMBER: 1996-61128 VETU

TITLE: Determination of pre-clinical effects and clinical efficacy
of organ preparations.
(Praeklinische wirkungs- und klinische wirksamkeitsnachweise
von organpraeparaten)

AUTHOR: Schmid F

LOCATION: Aschaffenburg, Ger.

SOURCE: Tieraerztl.Umsch. (51, No. 2, 63-68, 1996) 4 Fig. 5 Tab. 9
Ref.

CODEN: TIEUA7

AVAIL. OF DOC.: Ziegelbergstrasse 17, 63739 Aschaffenburg, Germany.

LANGUAGE: German

DOCUMENT TYPE: Journal

FIELD AVAIL.: AB; LA; CT

AN 1996-61128 VETU

AB The Author discusses the effects and clinical efficacy of organ
preparations, including growth factors, cytokines and peptides, such as
osteoinductive factor (OIF), osteogenin, bone morphogenic factor (BMF),
transforming growth factor (TGF), bone-derived growth factor (BDGF),
platelet-derived growth factor (PDGF), insulin-like growth factor (IGF),
nerve growth factor (NGF), brain-derived neuronal factor (BDNF), ciliary
neurotrophic factor (CTTF), ganglion/facial motorneurone factors,
neurotrophin 3 (NT3), basic fibroblast growth factor (bFGF) and epidermal
growth factor (EGF) and various activating factors (interleukins, IL,
mitogenic factors, complement components, transferrin), suppressing
factors (inhibiting factors, IFN, c-reactive protein, alpha feto protein,
fibrinogen), factors of inflammation and direct acting factors.

ABEX Organ preparations include unprepared or processed organs, tissue
cells, **homeopathic** preparations, cell fractions and enzymes.
Bone-derived growth factors include OIF, osteogenin, BMF-1, 2, 3, TGF-1,
2, alpha/beta FGF, BDGF, PDGF and **IGF-1**, 2.
Activating factors include IL-1, 2, 3, complement components,
transferrin, mitogenic protein and normal macrophage, C-cell activating,
thymus differentiation, mitogenic-blastogenic, T-cell-derived enhancing
and thymus-extracted fractions. Suppressing factors include DNA
synthesis inhibitors, antibody inhibiting material, soluble immune
response suppressor, immunoregulatory alphaglobulin, IFN, alpha feto
protein, LDL, c-reactive protein, fibrinogen, normal immunosuppressive
protein, low molecular weight suppressor and histamine induced
suppressive, T-cell suppressive, lymphoblastogenesis inhibiting, feedback
inhibiting and migration inhibition factor (MIF)-inhibiting factors.
Growth factors affecting nerve tissue include NGF, BDNF, CNTF, ciliary
ganglion/facial nerve motorneurone factors, NT3, PDGF, bFGF and EGF.
Factors of inflammation include pyrogens, slow reacting substance of
allergy, TX, PG, LT, IFN, MIF, macrophage activating/enhancement factors,
fibroblast activating factor, eosinophil stimulation promotor and various
blood cell inhibition and chemotactic factors. Direct acting factors
include lysosomal enzymes, lymphotoxin, (macrophage) cytotoxic factor,
adherent cell toxin, microbial factors, leucoregulin, and macrophage
cytolytic, proliferation inhibiting, cloning inhibition and tumor
necrosis factors.

=>

L9 ANSWER 1 OF 10 USPATFULL on STN
ACCESSION NUMBER: 2003:271454 USPATFULL
TITLE: Treatment methods using homeopathic preparations of
growth factors
INVENTOR(S): Brewitt, Barbara A., Seattle, WA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003191061	A1	20031009
APPLICATION INFO.:	US 2002-304635	A1	20021126 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2000-499230, filed on 7 Feb 2000, GRANTED, Pat. No. US 6485480 Division of Ser. No. US 1997-855096, filed on 13 May 1997, GRANTED, Pat. No. US 6024734 Continuation-in-part of Ser. No. US 1996-710040, filed on 10 Sep 1996, GRANTED, Pat. No. US 5629286 Continuation of Ser. No. US 1995-488722, filed on 8 Jun 1995, ABANDONED Continuation-in-part of Ser. No. US 1994-221365, filed on 31 Mar 1994, ABANDONED Continuation-in-part of Ser. No. US 2001-1367, filed on 30 Oct 2001, PENDING Continuation-in-part of Ser. No. US 2001-870132, filed on 29 May 2001, ABANDONED Continuation of Ser. No. US 1999-251820, filed on 17 Feb 1999, GRANTED, Pat. No. US 6239105 Continuation-in-part of Ser. No. US 1997-855096, filed on 13 May 1997, GRANTED, Pat. No. US 6024734 Continuation-in-part of Ser. No. US 1996-710040, filed on 10 Sep 1996, GRANTED, Pat. No. US 5629286 Continuation of Ser. No. US 1995-488722, filed on 8 Jun 1995, ABANDONED Continuation-in-part of Ser. No. US 1994-221365, filed on 31 Mar 1994, ABANDONED		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	SPECKMAN LAW GROUP, 1501 WESTERN AVE, SUITE 100, SEATTLE, WA, 98101		
NUMBER OF CLAIMS:	14		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	35 Drawing Page(s)		
LINE COUNT:	2546		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention comprises homeopathic preparations of growth factors, cyclins, and methods for their use. Disorders which may be effectively treated with the compositions of the present invention include chronic viral disorders, such as HIV, AIDS, chronic fatigue syndrome and Epstein-Barr viral infections, cancer, diabetes, depression, and autism. Homeopathic preparations of growth factors and/or cyclins are preferably administered orally. In an alternative embodiment, patients are treated with radio frequency signals corresponding to homeopathic dilutions of growth factors.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 2 OF 10 PROMT COPYRIGHT 2004 Gale Group on STN

ACCESSION NUMBER: 2002:181936 PROMT
TITLE: Joshua Tree, dba Nutritionary, Announces the Release of
Three Weight Loss Products.
SOURCE: Business Wire, (25 Mar 2002) pp. 2341.
PUBLISHER: Business Wire
DOCUMENT TYPE: Newsletter
LANGUAGE: English
WORD COUNT: 775
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

AB Business Editors/Health & Medical Writers
THIS IS THE FULL TEXT: COPYRIGHT 2002 Business Wire

L9 ANSWER 3 OF 10 USPATFULL on STN DUPLICATE 1
ACCESSION NUMBER: 2002:92896 USPATFULL
TITLE: Homeopathic preparations
INVENTOR(S): Brewitt, Barbara A., Seattle, WA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002049422	A1	20020425
APPLICATION INFO.:	US 2001-1367	A1	20011030 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2001-870132, filed on 29 May 2001, PENDING Continuation of Ser. No. US 1999-251820, filed on 17 Feb 1999, PATENTED Continuation-in-part of Ser. No. US 1997-855096, filed on 13 May 1997, PATENTED Continuation-in-part of Ser. No. US 1996-710040, filed on 10 Sep 1996, PATENTED Continuation of Ser. No. US 1995-488722, filed on 8 Jun 1995, ABANDONED Continuation-in-part of Ser. No. US 1994-221365, filed on 31 Mar 1994, ABANDONED		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-255958P	20001215 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Ann W. Speckman, SPECKMAN LAW GROUP, Suite 100, 1501 Western Avenue, Seattle, WA, 98101	
NUMBER OF CLAIMS:	15	
EXEMPLARY CLAIM:	1	
LINE COUNT:	951	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

AB The present invention comprises homeopathic preparations of a purified protein described herein, as well as methods and systems for delivery of such preparations and treatment of disorders and conditions by administering such preparations.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 4 OF 10 USPATFULL on STN DUPLICATE 2
ACCESSION NUMBER: 2002:310444 USPATFULL
TITLE: Treatment methods using homeopathic preparations of growth factors
INVENTOR(S): Brewitt, Barbara A., 5557 36thAve. NE., Seattle, WA, United States 98105

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6485480	B1	20021126
APPLICATION INFO.:	US 2000-499230		20000207 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1997-855096, filed on 13 May 1997, now patented, Pat. No. US 6024734 Continuation-in-part of Ser. No. US 1996-710040, filed on 10 Sep 1996, now patented, Pat. No. US 5629286, issued on 13 May 1997 Continuation of Ser. No. US 1995-488722, filed on 8 Jun 1995, now abandoned Continuation-in-part of Ser. No. US 1994-221365, filed on 31 Mar 1994, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Casler, Brian L.		
ASSISTANT EXAMINER:	Thissell, Jeremy		

LEGAL REPRESENTATIVE: Speckman, Ann W., Klaniecki, James E., Benado, Lisa N.
NUMBER OF CLAIMS: 16
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 38 Drawing Figure(s); 34 Drawing Page(s)
LINE COUNT: 1892

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention comprises homeopathic dilutions of growth factors and methods for their use. Disorders which may be effectively treated with the compositions of the present invention include chronic viral disorders, such as HIV, AIDS, chronic fatigue syndrome and Epstein-Barr viral infections, cancer, diabetes and depression. Homeopathic dilutions of growth factors are preferably administered orally. In an alternative embodiment, patients are treated with radio frequency signals corresponding to homeopathic dilutions of growth factors.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 5 OF 10 USPATFULL on STN
ACCESSION NUMBER: 2002:140892 USPATFULL
TITLE: Homeopathic preparations
INVENTOR(S): Brewitt, Barbara A., Seattle, WA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002071873	A1	20020613
APPLICATION INFO.:	US 2001-870132	A1	20010529 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1999-251820, filed on 17 Feb 1999, PATENTED Continuation-in-part of Ser. No. US 1997-855096, filed on 13 May 1997, PATENTED Continuation-in-part of Ser. No. US 1996-710040, filed on 10 Sep 1996, PATENTED Continuation of Ser. No. US 1995-488722, filed on 8 Jun 1995, ABANDONED Continuation-in-part of Ser. No. US 1994-221365, filed on 31 Mar 1994, ABANDONED		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	SPECHMAN LAW GROUP, 1501 WESTERN AVE, SUITE 100, SEATTLE, WA, 98101		
NUMBER OF CLAIMS:	1		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	16 Drawing Page(s)		
LINE COUNT:	1014		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention comprises homeopathic preparations of a purified growth factor, as well as methods and systems for delivery of such preparations and treatment of disorders and conditions by administering such preparations.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 6 OF 10 PROMT COPYRIGHT 2004 Gale Group on STN

ACCESSION NUMBER: 2001:316693 PROMT
TITLE: Biomed Comm Homeopathic Preparation Chewable Tablets - Ease
MANUFACTURER: Biomed Comm, Inc. CATEGORY: 350 - Pain Relief.
SOURCE: Product Alert, (23 Apr 2001) Vol. 31, No. 8.
ISSN: 0740-3801.
PUBLISHER: Marketing Intelligence Service Ltd.
DOCUMENT TYPE: Newsletter
LANGUAGE: English
WORD COUNT: 80
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

AB The Biomed Comm line of **Homeopathic** Preparation products includes Ease. The Chewable Tablets are sold in a 15-count plastic bottle that states, "Reliable fast relief." Its formula, said to use a 6C pure recombinant **IGF-1**, "may relieve many physical and psychological discomforts due to cyclical hormonal imbalance, including breast tenderness, joint soreness, headaches, cramps and bloating." The product is manufactured by Biomed Comm, Inc., located in Seattle, WA. For sample retrieval information, please call: Marketing Intelligence Service, Ltd., (716) 374-6326.

THIS IS THE FULL TEXT: COPYRIGHT 2001 Marketing Intelligence Service Ltd.

Subscription: \$600.00 per year. Published semimonthly. 6473 D Route 64, Naples, NY 14512-9726.

L9 ANSWER 7 OF 10 USPATFULL on STN

ACCESSION NUMBER: 2001:79130 USPATFULL
TITLE: Homeopathic preparations of purified growth hormone
INVENTOR(S): Brewitt, Barbara A., 5557 36th Ave. NE., Seattle, WA, United States 98107
PATENT ASSIGNEE(S): Brewitt, Barbara A., Seattle, WA, United States (U.S. individual)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6239105	B1	20010529
APPLICATION INFO.:	US 1999-251820		19990217 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1997-855096, filed on 13 May 1997, now patented, Pat. No. US 6024734 Continuation-in-part of Ser. No. US 1996-710040, filed on 10 Sep 1996, now patented, Pat. No. US 5629286, issued on 13 May 1997 Continuation of Ser. No. US 1995-488722, filed on 8 Jun 1995, now abandoned Continuation-in-part of Ser. No. US 1994-221365, filed on 31 Mar 1994, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Moezie, F. T.		
LEGAL REPRESENTATIVE:	Speckman, Ann W.		
NUMBER OF CLAIMS:	19		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	31 Drawing Figure(s); 16 Drawing Page(s)		
LINE COUNT:	1063		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention comprises homeopathic preparations of purified growth hormone, as well as methods and systems for delivery of such preparations and treatment of disorders and conditions by administering such preparations.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 8 OF 10 USPATFULL on STN

DUPLICATE 3

ACCESSION NUMBER: 2000:17822 USPATFULL
TITLE: Treatment methods using homeopathic preparations of growth factors
INVENTOR(S): Brewitt, Barbara A., 5557 36.sup.th Ave. NE., Seattle, WA, United States 98105

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6024734		20000215
APPLICATION INFO.:	US 1997-855096		19970513 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1996-710040, filed on 10 Sep 1996, now patented, Pat. No. US 5629286,		

issued on 13 May 1997 which is a continuation of Ser.
No. US 1995-488722, filed on 8 Jun 1995, now abandoned
which is a continuation-in-part of Ser. No. US
1994-221365, filed on 31 Mar 1994, now abandoned

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: McDermott, Corrine
ASSISTANT EXAMINER: Gring, Kent
LEGAL REPRESENTATIVE: Speckman, Ann W., Sleath, Janet
NUMBER OF CLAIMS: 21
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 30 Drawing Figure(s); 34 Drawing Page(s)
LINE COUNT: 2005

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention comprises homeopathic dilutions of growth factors and methods for their use. Disorders which may be effectively treated with the compositions of the present invention include chronic viral disorders, such as HIV, AIDS, chronic fatigue syndrome and Epstein-Barr viral infections, cancer, diabetes and depression. Homeopathic dilutions of growth factors are preferably administered orally. In an alternative embodiment, patients are treated with radio frequency signals corresponding to homeopathic dilutions of growth factors.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 9 OF 10 WPIDS COPYRIGHT 2004 THOMSON DERWENT on STN DUPLICATE 4

ACCESSION NUMBER: 2000-587749 [56] WPIDS
CROSS REFERENCE: 1995-358410 [46]; 1997-280299 [25]; 2000-181780 [16];
2002-425533 [45]; 2003-310423 [30]; 2003-831663 [77]

DOC. NO. CPI: C2000-175390

TITLE: Novel **homeopathic** preparation comprising a
homeopathic potency of purified growth hormone
for modulating effects of aging, reducing blood pressure,
increasing serum insulin-like growth factor levels, lean
body mass.

DERWENT CLASS: B04 D16

INVENTOR(S): BREWITT, B A

PATENT ASSIGNEE(S): (BIOM-N) BIOMED COMM INC; (BREW-I) BREWITT B A

COUNTRY COUNT: 4

PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
AU 2000018455	A	20000824	(200056)*		21
JP 2000302691	A	20001031	(200059)		16
ZA 2000000771	A	20001227	(200103)		21
US 6239105	B1	20010529	(200132)		
US 2002071873	A1	20020613	(200243)		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
AU 2000018455	A	AU 2000-18455	20000217
JP 2000302691	A	JP 2000-38624	20000216
ZA 2000000771	A	ZA 2000-771	20000217
US 6239105	B1	CIP of	US 1994-221365
		Cont of	US 1995-488722
		CIP of	US 1996-710040
		CIP of	US 1997-855096
			US 1999-251820
US 2002071873	A1	CIP of	US 1994-221365
		Cont of	US 1995-488722

CIP of	US 1996-710040	19960910
CIP of	US 1997-855096	19970513
Cont of	US 1999-251820	19990217
	US 2001-870132	20010529

FILING DETAILS:

PATENT NO	KIND	PATENT NO
US 6239105	B1 CIP of	US 5629286
	CIP of	US 6024734

PRIORITY APPLN. INFO: US 1999-251820 19990217; US
1994-221365 19940331; US
1995-488722 19950608; US
1996-710040 19960910; US
1997-855096 19970513; US
2001-870132 20010529

AN 2000-587749 [56] WPIDS
CR 1995-358410 [46]; 1997-280299 [25]; 2000-181780 [16]; 2002-425533 [45];
2003-310423 [30]; 2003-831663 [77]
AB AU 200018455 A UPAB: 20031128

NOVELTY - A **homeopathic** preparation (I) comprising a
homeopathic potency of purified growth hormone, is new.

ACTIVITY - Nootropic; neuroprotective; antiparkinsonian; osteopathic.
No supporting data given.

MECHANISM OF ACTION - Growth promoter; regulator of cell growth and
differentiation.

Studies were conducted on healthy adult subjects to ascertain the
effect of various potencies of recombinant human growth hormone (rhGH).
Three studies were conducted in the format of double-blind, placebo
controlled studies (DBPCS). In the first study, which was a thirty day
DBPCS, subjects were randomly divided into two groups; one group received
a combination 6C+100C+200C **homeopathic** hGH formulation and the
other group received placebo. In the second study, individuals were given
a placebo in a bottle and instructed to take one chewable tablet three
times per day for seven days and after seven days of treatment, subjects
were given a bottle which contained a single potency of either 6X or 6C or
placebo. The third study was a placebo controlled study with crossover
after 21 days to the opposite test substance. A group initially received
placebo and after 21 days received treatment with a **homeopathic**
preparation. Blood samples were taken from all the groups to determine
serum **IGF-1** levels. Reproducible rises in serum
IGF-1 were observed in all three studies.

USE - For modulating the effects of aging and for modulating lean
body mass (claimed). (I) has significant anabolic and anti-catabolic
effects on the body and is useful for increasing serum **IGF-1**
levels, lean body mass, muscle mass, libido and sex hormones,
energy levels, cartilage strength, and size and function of the thymus,
spleen, treating growth deficiency disorders, improving cardiovascular
function, endurance, skin tone, lipoprotein balance, fatty acid levels,
and cholesterol profile, enhancing immune system function, promoting hair
growth and color change, reducing blood pressure, joint, back and knee
pain, bleeding of the gums, nasal and sinus congestion, and fat, in
particular, hip size, upper arm size and waist size. (I) is also useful
for improving short term memory, reducing the manifestations of anger,
anxiety, depression, social isolation, mood swings and sleeping disorders,
improving vision, removing wrinkles, accelerating wound healing,
facilitating breast enlargement and generally contributing to a feeling of
well-being. (I) may also be useful to treat headaches, AIDS wasting
syndrome, Turner syndrome, osteoporosis, Parkinson's, Alzheimer's disease
and dementia.

ADVANTAGE - (I) is non-toxic, do not produce undesirable side effects

and can be formulated and provided to a large patient population at a reasonable cost by means of delivery systems that are convenient and safe.
Dwg.0/0

L9 ANSWER 10 OF 10 VETU COPYRIGHT 2004 THOMSON DERWENT on STN

ACCESSION NUMBER: 1996-61128 VETU

TITLE: Determination of pre-clinical effects and clinical efficacy of organ preparations.
(Praeklinische wirkungs- und klinische wirksamkeitsnachweise von organpraeparaten)

AUTHOR: Schmid F

LOCATION: Aschaffenburg, Ger.

SOURCE: Tieraerztl.Umsch. (51, No. 2, 63-68, 1996) 4 Fig. 5 Tab. 9 Ref.

CODEN: TIEUA7

AVAIL. OF DOC.: Ziegelbergstrasse 17, 63739 Aschaffenburg, Germany.

LANGUAGE: German

DOCUMENT TYPE: Journal

FIELD AVAIL.: AB; LA; CT

AN 1996-61128 VETU

AB The Author discusses the effects and clinical efficacy of organ preparations, including growth factors, cytokines and peptides, such as osteoinductive factor (OIF), osteogenin, bone morphogenic factor (BMF), transforming growth factor (TGF), bone-derived growth factor (BDGF), platelet-derived growth factor (PDGF), insulin-like growth factor (IGF), nerve growth factor (NGF), brain-derived neuronal factor (BDNF), ciliary neurotrophic factor (CTTF), ganglion/facial motoneurone factors, neurotrophin 3 (NT3), basic fibroblast growth factor (bFGF) and epidermal growth factor (EGF) and various activating factors (interleukins, IL, mitogenic factors, complement components, transferrin), suppressing factors (inhibiting factors, IFN, c-reactive protein, alpha feto protein, fibrinogen), factors of inflammation and direct acting factors.

ABEX Organ preparations include unprepared or processed organs, tissue cells, **homeopathic** preparations, cell fractions and enzymes. Bone-derived growth factors include OIF, osteogenin, BMF-1, 2, 3, TGF-1, 2, alpha/beta FGF, BDGF, PDGF and **IGF-1**, 2. Activating factors include IL-1, 2, 3, complement components, transferrin, mitogenic protein and normal macrophage, C-cell activating, thymus differentiation, mitogenic-blastogenic, T-cell-derived enhancing and thymus-extracted fractions. Suppressing factors include DNA synthesis inhibitors, antibody inhibiting material, soluble immune response suppressor, immunoregulatory alphaglobulin, IFN, alpha feto protein, LDL, c-reactive protein, fibrinogen, normal immunosuppressive protein, low molecular weight suppressor and histamine induced suppressive, T-cell suppressive, lymphoblastogenesis inhibiting, feedback inhibiting and migration inhibition factor (MIF)-inhibiting factors. Growth factors affecting nerve tissue include NGF, BDNF, CNTF, ciliary ganglion/facial nerve motoneurone factors, NT3, PDGF, bFGF and EGF. Factors of inflammation include pyrogens, slow reacting substance of allergy, TX, PG, LT, IFN, MIF, macrophage activating/enhancement factors, fibroblast activating factor, eosinophil stimulation promoter and various blood cell inhibition and chemotactic factors. Direct acting factors include lysosomal enzymes, lymphotoxin, (macrophage) cytotoxic factor, adherent cell toxin, microbial factors, leucoregulin, and macrophage cytolytic, proliferation inhibiting, cloning inhibition and tumor necrosis factors.

=>